PT - JOURNAL ARTICLE AU - Julia Debik AU - Hartmut Schaefer AU - Trygve Andreassen AU - Feng Wang AU - Fang Fang AU - Claire Cannet AU - Manfred Spraul AU - Tone F. Bathen AU - Guro F. Giskeødegård TI - Lipoprotein and metabolite associations to breast cancer risk in the HUNT2 study AID - 10.1101/2021.10.08.21264729 DP - 2021 Jan 01 TA - medRxiv PG - 2021.10.08.21264729 4099 - http://medrxiv.org/content/early/2021/10/11/2021.10.08.21264729.short 4100 - http://medrxiv.org/content/early/2021/10/11/2021.10.08.21264729.full AB - Background The aim of this study was to investigate if serum lipoprotein and metabolic profiles of healthy women can predict the risk of developing breast cancer in the future, and to gain a better understanding of the etiology of the disease.Methods From a cohort of 70 000 participants within the Trøndelag Health Study (HUNT study), we identified 1199 women who developed breast cancer within a 22 year follow-up period. Through a nested case-control study design, future breast cancer patients and matching controls (n = 2398) were analysed. Using nuclear magnetic resonance (NMR) spectroscopy, 28 metabolites and 112 lipoprotein subfractions were quantified from prediagnostic serum samples. Logistic regression was used to test metabolites and lipoprotein subfractions for associations with breast cancer risk and partial least-squares discriminant analysis (PLS-DA) models were built to predict future disease.Results Among premenopausal women (554 cases) 14 lipoprotein subfractions were associated with long-term breast cancer risk. In specific, different subfractions of VLDL particles (in particular VLDL-2, VLDL-3 and VLDL-4) were inversely associated with breast cancer. For total VLDL: apolipoprotein B, cholesterol, free cholesterol and phospholipids were inversely associated with premenopausal breast cancer risk, and in addition total and HDL-4 triglycerides. No significant association was found in postmenopausal women.Conclusions We identified several associations between lipoprotein subfractions and long-term risk of breast cancer in premenopausal women. Inverse associations between several VLDL subfractions and breast cancer risk were found, revealing an altered metabolism in the endogenous lipid pathway many years prior to a breast cancer diagnosis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work has been supported by the Norwegian Financial Mechanism 2014-2021, Project 2019/34/H/NZ7/00503) the Cancer Society (6834362 and 202021); Bruker BioSpin; Kreftfondet; NTNU Smaforsk; Stiftelsen DAM (2020/FO298770); and the Liaison Committee for education, research and innovation in Central Norway (2020/3806-4 and 28346). GFG works in a research unit funded by Stiftelsen Kristian Gerhard Jebsen; Faculty of Medicine and Health Sciences, NTNU; the Liaison Committee for education, research and innovation in Central Norway; and the Joint Research Committee between St. Olavs Hospital and the Faculty of Medicine and Health Sciences, NTNU.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics Committee of Central Norway (REK numbers #1995/8395 and #2017/2231).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesTo protect participants privacy, HUNT Research Centre aims to limit storage of data outside HUNT databank, and cannot deposit data in open repositories. HUNT databank has precise information on all data exported to different projects and are able to reproduce these on request. There are no restrictions regarding data export given approval of applications to HUNT Research Centre. For more information see: http://www.ntnu.edu/hunt/data.